ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Phaedrus
|
5.7K |
2.8M |
33 |
18/08/24 |
18/08/24 |
ASX - By Stock
|
5.7K
|
2.8M
|
33
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
10K |
3.2M |
13 |
17/08/24 |
17/08/24 |
ASX - By Stock
|
10K
|
3.2M
|
13
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
10K |
3.2M |
5 |
17/08/24 |
17/08/24 |
ASX - By Stock
|
10K
|
3.2M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
10K |
3.2M |
6 |
17/08/24 |
17/08/24 |
ASX - By Stock
|
10K
|
3.2M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
10K |
3.2M |
18 |
17/08/24 |
17/08/24 |
ASX - By Stock
|
10K
|
3.2M
|
18
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
10K |
3.2M |
30 |
17/08/24 |
17/08/24 |
ASX - By Stock
|
10K
|
3.2M
|
30
|
|
ASX - By Stock
|
MSB |
Re:
Back pain trial
|
|
Phaedrus
|
35 |
9.6K |
6 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
35
|
9.6K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Pick Today's Price Range Low-High... Just for Fun
|
|
Phaedrus
|
1.3K |
406K |
3 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
1.3K
|
406K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Phaedrus
|
132 |
41K |
11 |
02/08/24 |
02/08/24 |
ASX - By Stock
|
132
|
41K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Phaedrus
|
132 |
41K |
22 |
01/08/24 |
01/08/24 |
ASX - By Stock
|
132
|
41K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
406K |
7 |
27/07/24 |
27/07/24 |
ASX - By Stock
|
943
|
406K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
NASDAQ hot!!!
|
|
Phaedrus
|
675 |
304K |
25 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
675
|
304K
|
25
|
|
ASX - By Stock
|
MSB |
Re:
CLBP Trial 2024
|
|
Phaedrus
|
13 |
5.8K |
38 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
13
|
5.8K
|
38
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
10K |
3.2M |
6 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
10K
|
3.2M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
10K |
3.2M |
0 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
10K
|
3.2M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
10K |
3.2M |
4 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
10K
|
3.2M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
once approved
|
|
Phaedrus
|
131 |
54K |
20 |
13/07/24 |
13/07/24 |
ASX - By Stock
|
131
|
54K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
once approved
|
|
Phaedrus
|
131 |
54K |
14 |
13/07/24 |
13/07/24 |
ASX - By Stock
|
131
|
54K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Resubmits BLA with FDA for Ryoncil Approval
|
|
Phaedrus
|
265 |
105K |
5 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
265
|
105K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Phaedrus
|
5.7K |
2.8M |
13 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
5.7K
|
2.8M
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Resubmits BLA with FDA for Ryoncil Approval
|
|
Phaedrus
|
265 |
105K |
6 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
265
|
105K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Resubmits BLA with FDA for Ryoncil Approval
|
|
Phaedrus
|
265 |
105K |
16 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
265
|
105K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Resubmits BLA with FDA for Ryoncil Approval
|
|
Phaedrus
|
265 |
105K |
21 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
265
|
105K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
406K |
2 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
943
|
406K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
406K |
21 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
943
|
406K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Phaedrus
|
5.7K |
2.8M |
4 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
5.7K
|
2.8M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Phaedrus
|
5.7K |
2.8M |
9 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
5.7K
|
2.8M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
10K |
3.2M |
24 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
10K
|
3.2M
|
24
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
10K |
3.2M |
6 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
10K
|
3.2M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
438K |
26 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
1.0K
|
438K
|
26
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
84K |
18 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
84K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
84K |
5 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
84K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
84K |
2 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
84K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
84K |
6 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
84K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
84K |
11 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
84K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
84K |
2 |
16/06/24 |
16/06/24 |
ASX - By Stock
|
225
|
84K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
438K |
7 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
1.0K
|
438K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
438K |
9 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
1.0K
|
438K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
438K |
8 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
1.0K
|
438K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
438K |
4 |
15/06/24 |
15/06/24 |
ASX - By Stock
|
1.0K
|
438K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
438K |
14 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
1.0K
|
438K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
438K |
15 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
1.0K
|
438K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
10K |
3.2M |
8 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
10K
|
3.2M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Phaedrus
|
10K |
3.2M |
7 |
14/06/24 |
14/06/24 |
ASX - By Stock
|
10K
|
3.2M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
dividend
|
|
Phaedrus
|
8 |
3.2K |
12 |
13/06/24 |
13/06/24 |
ASX - By Stock
|
8
|
3.2K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
84K |
20 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
225
|
84K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
84K |
6 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
225
|
84K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
84K |
22 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
225
|
84K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
406K |
16 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
943
|
406K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Australian newspaper article
|
|
Phaedrus
|
225 |
84K |
24 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
225
|
84K
|
24
|
|